Evidence map›Paper›PMID 31652296›Full record

ArticlePLoS pathogens2019

Oxamniquine resistance alleles are widespread in Old World Schistosoma mansoni and predate drug deployment.

Frédéric D Chevalier, Winka Le Clec'h, Marina McDew-White, Vinay Menon, Meghan A Guzman, Stephen P Holloway, Xiaohang Cao, Alexander B Taylor, Safari Kinung'hi, Anouk N Gouvras and 13 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 40 citations in OpenAlex.

  1. Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Chemistry and Bioactivity ofMolecules (Basel, Switzerland) · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 8 countries.

Frédéric D ChevalierTexas Biomedical Research Institute, San Antonio, Texas, United States of America.ORCID 0000-0003-2611-8106
Winka Le Clec'hTexas Biomedical Research Institute, San Antonio, Texas, United States of America.
Marina McDew-WhiteTexas Biomedical Research Institute, San Antonio, Texas, United States of America.
Vinay MenonTexas Biomedical Research Institute, San Antonio, Texas, United States of America.
Meghan A GuzmanDepartments of Pathology and University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America.
Stephen P HollowayBiochemistry & Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America.
Xiaohang CaoBiochemistry & Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America.
Alexander B TaylorBiochemistry & Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America.ORCID 0000-0003-3517-6033
Safari Kinung'hiNational Institute for Medical Research, Mwanza, United Republic of Tanzania.
Anouk N GouvrasLondon Centre for Neglected Tropical Disease Research (LCNDTR), Imperial Collge, London, United Kingdom.ORCID 0000-0002-7857-4309
Bonnie L WebsterLondon Centre for Neglected Tropical Disease Research (LCNDTR), Imperial Collge, London, United Kingdom.ORCID 0000-0003-0930-9314
Joanne P WebsterLondon Centre for Neglected Tropical Disease Research (LCNDTR), Imperial Collge, London, United Kingdom.ORCID 0000-0001-8616-4919
Aidan M EmeryLondon Centre for Neglected Tropical Disease Research (LCNDTR), Imperial Collge, London, United Kingdom.ORCID 0000-0001-9028-8586
David RollinsonLondon Centre for Neglected Tropical Disease Research (LCNDTR), Imperial Collge, London, United Kingdom.
Amadou Garba DjirmayRéseau International Schistosomiases Environnemental Aménagement et Lutte (RISEAL), Niamey, Niger.
Khalid M Al MashikhiDirectorate General of Health Services, Dhofar Governorate, Salalah, Sultanate of Oman.
Salem Al YafaeDirectorate General of Health Services, Dhofar Governorate, Salalah, Sultanate of Oman.
Mohamed A IdrisSultan Qaboos University, Muscat, Sultanate of Oman.
Hélène MonéHost-Pathogen-Environment Interactions laboratory, University of Perpignan, Perpignan, France.ORCID 0000-0003-3180-344X
Gabriel MouahidHost-Pathogen-Environment Interactions laboratory, University of Perpignan, Perpignan, France.ORCID 0000-0003-0332-5081
P John HartBiochemistry & Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America.
Philip T LoVerdeDepartments of Pathology and University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America.
Timothy J C AndersonTexas Biomedical Research Institute, San Antonio, Texas, United States of America.ORCID 0000-0002-0191-0204
The University of Texas Health Science Center at San Antonio · USTexas Biomedical Research Institute · USNatural History Museum · GBDirectorate General of Health Services · BDUniversité de Perpignan · FRCentre de Recherche Médicale et Sanitaire · NENational Institute for Medical Research · TZSultan Qaboos University · OMUniversity of London · GB

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
Institute for Integration of Medicine & Science: A Partnership to Improve HealthUL1TR001120 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, HARGREAVES, KENNETH M · 2013 to 2017
$16.5M
Genetic Basis of Praziquantel ResistanceR01AI123434 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J, LOVERDE, PHILIP T · 2016 to 2020
$3.5M
Structure-guided redesign of an antischistosomal drugR01AI115691 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LOVERDE, PHILIP T · 2015 to 2019
$2.6M
Genetic analysis of cercarial release in schistosomesR01AI133749 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J · 2017 to 2021
$2.5M
High Performance Computing System for Human GenomicsS10RR029392 · NCRR · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI BLANGERO, JOHN · 2010 to 2010
$2.1M
Genetic Analysis of Host Specificity in Schistosoma mansoniR01AI097576 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J · 2012 to 2014
$1.7M
Modeling Drug Induced Resistance in S. mansoni Endemic AreasP50AI098507 · NIAID · FOUNDATION FOR RESEARCH DEVELOPMENT · PI OLIVEIRA, GUILHERME C · 2012 to 2016
$1.5M
Efficient Linkage Mapping Methods for Schistosoma mansoniR21AI096277 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J, LOVERDE, PHILIP T · 2012 to 2013
$453k
MOLECULAR AND BIOCHEMICAL GENETICS LABORATORY RENOVATIONC06RR013556 · NCRR · SOUTHWEST FOUNDATION FOR BIOMEDICAL RES · PI SHADE, ROBERT E · 1998 to 1998
–
NCATS NIH HHS UL1 TR001120NCI NIH HHS P30 CA054174NCRR NIH HHS C06 RR013556NCRR NIH HHS S10 RR029392NIAID NIH HHS P50 AI098507NIAID NIH HHS R01 AI097576NIAID NIH HHS R01 AI115691NIAID NIH HHS R01 AI123434NIAID NIH HHS R01 AI133749NIAID NIH HHS R21 AI096277Wellcome TrustWellcome Trust 104958/Z/14/Z
6 · The paper itself

Abstract

Do mutations required for adaptation occur de novo, or are they segregating within populations as standing genetic variation? This question is key to understanding adaptive change in nature, and has important practical consequences for the evolution of drug resistance. We provide evidence that alleles conferring resistance to oxamniquine (OXA), an antischistosomal drug, are widespread in natural parasite populations under minimal drug pressure and predate OXA deployment. OXA has been used since the 1970s to treat Schistosoma mansoni infections in the New World where S. mansoni established during the slave trade. Recessive loss-of-function mutations within a parasite sulfotransferase (SmSULT-OR) underlie resistance, and several verified resistance mutations, including a deletion (p.E142del), have been identified in the New World. Here we investigate sequence variation in SmSULT-OR in S. mansoni from the Old World, where OXA has seen minimal usage. We sequenced exomes of 204 S. mansoni parasites from West Africa, East Africa and the Middle East, and scored variants in SmSULT-OR and flanking regions. We identified 39 non-synonymous SNPs, 4 deletions, 1 duplication and 1 premature stop codon in the SmSULT-OR coding sequence, including one confirmed resistance deletion (p.E142del). We expressed recombinant proteins and used an in vitro OXA activation assay to functionally validate the OXA-resistance phenotype for four predicted OXA-resistance mutations. Three aspects of the data are of particular interest: (i) segregating OXA-resistance alleles are widespread in Old World populations (4.29-14.91% frequency), despite minimal OXA usage, (ii) two OXA-resistance mutations (p.W120R, p.N171IfsX28) are particularly common (>5%) in East African and Middle-Eastern populations, (iii) the p.E142del allele has identical flanking SNPs in both West Africa and Puerto Rico, suggesting that parasites bearing this allele colonized the New World during the slave trade and therefore predate OXA deployment. We conclude that standing variation for OXA resistance is widespread in S. mansoni.

Indexed as

Adaptation, PhysiologicalAllelesAnimalsCricetinaeDrug ResistanceHumansNigerOmanOxamniquinePolymorphism, Single NucleotideRatsSchistosoma mansoniSchistosomiasis mansoniSchistosomicidesSenegalSnailsOxamniquineSchistosomicides

Identifiers

PMID31652296
PMCPMC6834289
OpenAlexW2982048523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.